share_log

Amgen | 8-K: AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Amgen | 8-K: AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

安進 | 8-K:安進公佈2024年第二季度財務業績
美股SEC公告 ·  2024/08/07 04:10

Moomoo AI 已提取核心訊息

Amgen reported strong Q2 2024 financial results with total revenues increasing 20% to $8.4 billion, driven by 26% volume growth partially offset by 3% lower net selling price. Product sales grew 20% to $8.0 billion, including $1.1 billion from rare disease products. Twelve products achieved double-digit sales growth, including Prolia, EVENITY, Repatha, and TEZSPIRE.GAAP earnings per share decreased 46% to $1.38, impacted by higher operating expenses including Horizon-related amortization. Non-GAAP EPS declined slightly by 1% to $4.97. Operating margin decreased to 23.7% GAAP and 48.2% non-GAAP. The company generated $2.2 billion in free cash flow.The company maintained its full-year 2024 guidance with total revenues expected between $32.8-33.8 billion. GAAP EPS is projected at $6.57-7.62 and non-GAAP EPS at $19.10-20.10. Amgen remains on track to achieve over $10 billion in debt reduction by end of 2025, having reduced debt by $2.0 billion year-to-date.
Amgen reported strong Q2 2024 financial results with total revenues increasing 20% to $8.4 billion, driven by 26% volume growth partially offset by 3% lower net selling price. Product sales grew 20% to $8.0 billion, including $1.1 billion from rare disease products. Twelve products achieved double-digit sales growth, including Prolia, EVENITY, Repatha, and TEZSPIRE.GAAP earnings per share decreased 46% to $1.38, impacted by higher operating expenses including Horizon-related amortization. Non-GAAP EPS declined slightly by 1% to $4.97. Operating margin decreased to 23.7% GAAP and 48.2% non-GAAP. The company generated $2.2 billion in free cash flow.The company maintained its full-year 2024 guidance with total revenues expected between $32.8-33.8 billion. GAAP EPS is projected at $6.57-7.62 and non-GAAP EPS at $19.10-20.10. Amgen remains on track to achieve over $10 billion in debt reduction by end of 2025, having reduced debt by $2.0 billion year-to-date.
安進發佈了強勁的2024年第二季度財務業績,總收入增長20%,達到84億美金,主要受26%成交量增長的推動,部分被3%的淨銷售價格下降所抵消。產品銷售增長20%,達到80億美金,其中來自罕見疾病產品的收入爲11億美金。十二種產品實現了兩位數的銷售增長,包括Prolia、EVENITY、Repatha和TEZSPIRE。GAAP 每股收益下降46%,至1.38美金,受較高的營業費用影響,包括與Horizon相關的攤銷。非GAAP 每股收益略微下降1%,達到4.97美金。營業利潤率下降至23.7% GAAP和48.2%非GAAP。公司創造了22億美金的自由現金流。公司維持2024年全年的指引,預計總收入將在328-338億美金之間。GAAP 每股收益預計在6.57-7.62美金之間,非GAAP 每股收益預計在19.10-20.10美金之間。安進仍在計劃內,預計到2025年底實現超過100億美金的減債,年初至今已減少債務20億美金。
安進發佈了強勁的2024年第二季度財務業績,總收入增長20%,達到84億美金,主要受26%成交量增長的推動,部分被3%的淨銷售價格下降所抵消。產品銷售增長20%,達到80億美金,其中來自罕見疾病產品的收入爲11億美金。十二種產品實現了兩位數的銷售增長,包括Prolia、EVENITY、Repatha和TEZSPIRE。GAAP 每股收益下降46%,至1.38美金,受較高的營業費用影響,包括與Horizon相關的攤銷。非GAAP 每股收益略微下降1%,達到4.97美金。營業利潤率下降至23.7% GAAP和48.2%非GAAP。公司創造了22億美金的自由現金流。公司維持2024年全年的指引,預計總收入將在328-338億美金之間。GAAP 每股收益預計在6.57-7.62美金之間,非GAAP 每股收益預計在19.10-20.10美金之間。安進仍在計劃內,預計到2025年底實現超過100億美金的減債,年初至今已減少債務20億美金。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息